Systemic sclerosis - A systematic overview: Part 1 - Disease characteristics and classification, pathophysiologic concepts, and recommendations for diagnosis and surveillance

Vasa - Journal of Vascular Diseases

Volumn 40, Issue 1, 2011, Pages 6-19

  Klein Weigel, Peter ^a   Opitz, C ^a   Riemekasten, G ^b  

^a German Red Cross Hospital   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Capillary microscopy; Digital ulcer; Pulmonary arterial hypertension; Raynaud's phenomenon; Scleroderma disorder; Systemic sclerosis

Indexed keywords

CELL ADHESION MOLECULE; CONNECTIVE TISSUE GROWTH FACTOR; DNA TOPOISOMERASE; ENDOTHELIN 1; FIBRILLARIN; INTERLEUKIN 4; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; NERVE GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; RNA POLYMERASE; SCLEROPROTEIN; THROMBOMODULIN; TRANSFORMING GROWTH FACTOR BETA;

ADRENAL CORTEX INSUFFICIENCY; ANGIOGRAPHY; ATHEROSCLEROSIS; BILIARY CIRRHOSIS; BRONCHOSCOPY; CELLULAR IMMUNITY; CLINICAL FEATURE; DIGITAL IMAGING; DISEASE SURVEILLANCE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL DISEASE; HEART DISEASE; HUMAN; HUMORAL IMMUNITY; KIDNEY FUNCTION; LUNG DIFFUSION CAPACITY; LUNG DISEASE; LUNG FUNCTION TEST; MELANOMA; MIXED CONNECTIVE TISSUE DISEASE; PATHOPHYSIOLOGY; PLETHYSMOGRAPHY; PRIMARY BILIARY CIRRHOSIS; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; REVIEW; SPIROMETRY; SYSTEMIC SCLEROSIS; TOTAL LUNG CAPACITY; VITAL CAPACITY;

CAPILLARIES; EUROPE; HUMANS; HYPERTENSION, PULMONARY; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; RAYNAUD DISEASE; RISK FACTORS; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SOCIETIES, MEDICAL; TERMINOLOGY AS TOPIC; ULCER;

EID: 79251649154     PISSN: 03011526     EISSN: None     Source Type: Journal    
DOI: 10.1024/0301-1526/a000065     Document Type: Review

References (125)

1. Abraham DJ, Krieg T, Distler J, Distler O. Overview of pathogenesis of systemic sclerosis. Rheumatology 2009; 48 (Suppl 3): iii3-7.
2. Agarwal SK,Tan FK, Arnett FC. Genetics and genomic studies in scleroderma (systemic sclerosis). Rheum Dis Clin North Am 2008; 34: 17-40. (Pubitemid 351337628)
3. Ahmed SS, Tan FK, Arnett FC, et al. Induction of apoptosis and fibrillin 1 expression in human dermal endothelial cells by scleroderma sera containing anti-endothelial cell antibodies. Arthritis Rheum 2006; 54: 2250-62.
4. Akesson A, Wollheim FA. Organ manifestations in 100 patients with progressive systemic sclerosis: A comparison between the CREST syndrome and diffuse scleroderma. Br J Rheumatol 1989; 28: 281-6. (Pubitemid 19205920)
5. Allanore Y, Seror R, Chevrot A, Kahan A, Drapé JL. Hand vascular involvement assessed by magnetic resonance angiography in systemic sclerosis. Arthritis Rheum 2007; 56: 2747-54. (Pubitemid 47237294)
6. Allanore Y, Wipff J, Kahan A, Boileau C. Genetic basis for systemic sclerosis. Joint Bone Spine 2007; 74: 577-83.
7. Arnett FC, Howard RF, Tan F, Moulds JM, Bias WB, Durban E, Cameron HD, Paxton G, Hodge TJ, Weathers PE, Reveille JD. Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma. Association with an Amerindian HLA haplotype. Arthritis Rheum 1996; 39: 1362-1370.
8. Artlett CM. Microchimerism and scleroderma: an update. Curr Rheumatol Rep 2003; 5: 154-9.
9. Avouac J, Sordet C, Depinay C, Ardizonne M, Vacher-Lavenu MC, Sibilia J, Kahan A, Allanore Y. Systemic sclerosis-associated Sjögren's syndrome and relationship to the limited cutaneous subtype: results of a prospective study of sicca syndrome in 133 consecutive patients. Arthritis Rheum 2006; 54: 2243-9.
10. Avouac J, Guerini H, Wipff J, et al. Radiological hand involvement in systemic sclerosis. Ann Rheum Dis 2006; 65: 1088.
11. Barnett AJ, Miller M, Littlejohn GO. The diagnosis and classification of scleroderma (systemic sclerosis). Postgrad Med J 1988; 64: 121-5.
12. Baroni SS, Santillo M, Bevilacqua F, et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006; 354: 2667-76.
13. Biełous-Wilk A, Poreba M, Staniszewska-Marszałek E, Poreba R, Podgórski M, Kałka D, Jagielski D, Rusiecki L, Pilecki W, Baran E, Andrzejak R, Sobieszczańska M. Electrocardiographic evaluation in patients with systemic scleroderma and without clinically evident heart disease. Ann Noninvasive Electrocardiol 2009; 14: 251-7.
14. von Bierbrauer A, Barth P, Willert J, Baerwald C, Mennel HD, Schmidt JA. Electron microscopy and capillaroscopically guided nailfold biopsy in connective tissue diseases: detection of ultrastructural changes of the microcirculatory vessels. Br J Rheumatol 1998; 37: 1272-8.
15. Black CM. Scleroderma-clinical aspects. J Intern Med 1993; 234: 115-118.
16. Brown GE and O'Leary PA. Skin capillaries in scleroderma. Arch Intern Med 1925; 36: 73-88.
17. Bunn CC, Black CM. Systemic sclerosis: an autoantibody mosaic. Clin Exp Immunol 1999; 117: 207-8.
18. Carpentier PH, Maricq HR. Microvasculature in systemic sclerosis. Rheum Dis Clin North Am 1990; 16: 75-91.
19. Chung L, Lin J, Furst DE, Fiorentino D. Systemic and localized scleroderma. Clin Dermatol 2006; 24: 374-92.
20. Cipriani P, Guiducci S, Miniati I, Cinelli M, Urbani S, Marrelli A, Dolo V, Pavan A, Saccardi R, Tyndall A, Giacomelli R, Cerinic MM. Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis. Arthritis Rheum 2007; 56: 1994-2004.
21. Cutolo M, Sulli A, Pizzorni C, Accardo S. Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. J Rheumatol 2000; 27: 155-60. (Pubitemid 30058643)
22. Czirják L, Nagy Z, Aringer M, Riemekasten G, Matucci-Cerinic M, Furst DE; EUSTAR. The EUSTAR model for teaching and implementing the modified Rodnan skin score in systemic sclerosis. Ann Rheum Dis 2007; 66: 966-9.
23. Della Rossa A, Valentini G, Bombardieri S, Bencivelli W, Silman AJ, D'Angelo S, Cerinic MM, Belch JF, Black CM, Becvar R, Bruhlman P, Cozzi F, Czirják L, Drosos AA, Dziankowska B, Ferri C, Gabrielli A, Giacomelli R, Hayem G, Inanc M, McHugh NJ, Nielsen H, Scorza R, Tirri E, van den Hoogen FH, Vlachoyiannopoulos PG. European multicentre study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients from 19 centres. Ann Rheum Dis 2001; 60: 585-91.
24. Denton CP, Bickerstaff MC, Shiwen X, Carulli MT, Haskard DO, Dubois RM, Black CM. Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis. Br J Rheumatol 1995; 34: 1048.
25. Derk CT, Rasheed M, Artlett CM, Jimenez SA. A cohort study of cancer incidence in systemic sclerosis. J Rheumatol. 2006; 33: 1113-6.
26. Distler JH, Gay S, Distler O. Angiogenesis and vasculogenesis in systemic sclerosis. Rheumatology 2006; 45 (Suppl 3): iii26-7.
27. Distler JH, Jüngel A, Pileckyte M, Zwerina J, Michel BA, Gay RE, Kowal-Bielecka O, Matucci-Cerinic M, Schett G, Marti HH, Gay S, Distler O. Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis. Arthritis Rheum 2007; 56: 4203-15. (Pubitemid 350262349)
28. Distler O, Del Rosso A, Giacomelli R, Cipriani P, Conforti ML, Guiducci S, Gay RE, Michel BA, Brühlmann P, Müller-Ladner U, Gay S, Matucci-Cerinic M. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 2002; 4:R11.
29. Dragun D, Distler JH, Riemekasten G, Distler O. Stimulatory autoantibodies to platelet-derived growth factor receptors in systemic sclerosis: what functional autoimmunity could learn from receptor biology. Arthritis Rheum 2009; 60: 907-11.
30. Drosos AA, Andonopoulos AP, Costopoulos JS, Stavropoulos ED, Papadimitriou CS, Moutsopoulos HM. Sjögren's syndrome in progressive systemic sclerosis. J Rheumatol 1988; 15: 965-8.
31. Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G, Bullo A, Cazzato M, Tirri E, Storino F, Giuggioli D, Cuomo G, Rosada M, Bombardieri S, Todesco S, Tirri G; Systemic Sclerosis Study Group of the Italian Society of Rheumatology (SIR-GSSSc). Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine 2002; 81: 139-53.
32. Fineschi S, Cozzi F, Burger D, Dayer JM, Meroni PL, Chizzolini C. Anti-fibroblast antibodies detected by cell-based ELISA in systemic sclerosis enhance the collagenolytic activity and matrix metalloproteinase-1 production in dermal fibroblasts. Rheumatology 2007; 46: 1779-85.
33. Flavahan NA, Flavahan S, Mitra S, Chotani MA. The vasculopathy of Raynaud's phenomenon and scleroderma. Rheum Dis Clin North Am 2003; 29: 275-91.
34. Fleming JN, Nash RA, Mahoney WM Jr, Schwartz SM. Is scleroderma a vasculopathy? Curr Rheumatol Rep 2009; 11: 103-10.
35. Forbes A, Marie I. Gastrointestinal complications: the most frequent internal complications of systemic sclerosis. Rheumatology 2009; 48 (Suppl 3): iii36-9.
36. Fregeau DR, Leung PS, Coppel RL et al. Autoantibodies to mitochondia in systemic sclerosis. Frequency and characterization using recombinant cloned autoanigen. Arthritis Rheum 1988; 31: 386-92.
37. Genth E, Krieg T. Systemische Sklerose-Diagnose und Klassifi kation. Z Rheumatol 2006; 65: 268-74.
38. Goldin JG, Lynch DA, Strollo DC, Suh RD, Schraufnagel DE, Clements PJ, Elashoff RM, Furst DE, Vasunilashorn S, McNitt-Gray MF, Brown MS, Roth MD, Tashkin DP. Scleroderma Lung Study Research Group. High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease. Chest 2008; 134: 358-67.
39. Göring HD, Panzner M, Lakoota W, Ziemer A. Koinzidenz von Sklerodermie und primärerer biliärer Zirrhose. Ergebnisse einer systematischen Studie im dermatologischen Krankengut. Hautarzt 1998; 49: 361-6.
40. Granel B, Bernard F, Chevillard C. Genetic susceptibility to systemic sclerosis from clinical aspect to genetic factor analyses. Eur J Intern Med 2009; 20: 242-52.
41. de Groote P, Gressin V, Hachulla E, Carpentier P, Guillevin L, Kahan A, Cabane J, Francès C, Lamblin N, Diot E, Patat F, Sibilia J, Petit H, Cracowski JL, Clerson P, Humbert M. ItinerAIR-Scleroderma Investigators. Evaluation of cardiac abnormalities by Doppler echocardiography in a large nationwide multicentric cohort of patients with systemic sclerosis. Ann Rheum Dis 2008; 67: 31-6.
42. Gu YS, Kong J, Cheema GS, Keen CL, Wick G, Gershwin ME. The immunobiology of systemic sclerosis. Semin Arthritis Rheum 2008; 38: 132-60.
43. Guiducci S, Distler O, Distler JH, Matucci-Cerinic M. Mechanisms of vascular damage in SSc-implications for vascular treatment strategies. Rheumatology 2008; 47 (Suppl 5): v18-20.
44. Gupta RC, Seibolöd JR, Krishnan MR, Steigerwald JC. Precipitating autoantibodies to mitochondrial proteins in progressive systemic sclerosis. Clin Exp Immunolog 1984; 58: 68-76.
45. Hachulla E, Launay D, Yaici A, Berezne A, de Groote P, Sitbon O, Mouthon L, Guillevin L, Hatron PY, Simonneau G, Clerson P, Humbert M; on behalf of the French PAH-SSc Network. Pulmonary arterial hypertension associated with systemic sclerosis in patients with functional class II dyspnoea: mild symptoms but severe outcome. Rheumatology 2010 [Epub ahead of print].
46. Harper FE, Maricq HR, Turner RE, Lidman RW, Leroy EC. A prospective study of Raynaud phenomenon and early connective tissue disease. A five-year report. Am J Med 1982; 72: 883-8.
47. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 1997; 24: 328-32. (Pubitemid 27104098)
48. Hasegawa M, Nagi Y, Tamura A, Ishikawa O. arteriographic evaluation of vascular changes of the extremities in patients with systemic sclerosis. Br J Dermatol 2006; 155: 1159-64. (Pubitemid 44729989)
49. Heidrich H. Definition und Terminologie des Raynaud Syndroms. Dtsch Med Wochenschr 2008; 133: 1742-4.
50. Heidrich H, Helmis J, Fahrig C, Hövelmann R, Martini N. Clinical characteristics of primary, secondary and suspected secondary Raynaud's syndrome and diagnostic transition in the long-term follow-up. A retrospective study in 900 patients. VASA 2008;S73: 3-25.
51. Heidrich H. Functional vascular diseases: Raynaud's syndrome, acrocyanosis and erythromelalgia VASA 2010; 1: 33-41.
52. Henault J, Robitaille G, Senecal JL, Raymond Y. DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients. Arthritis Rheum 2006; 54: 963-73.
53. Hettema ME, Bootsma H, Kallenberg CG. Macrovascular disease and atherosclerosis in SSc. Rheumatology 2008; 47: 578-83.
54. Hill CL, Nguyen AM, Roder D, Roberts-Th omson P. Risk of cancer in patients with scleroderma: a population based cohort study. Ann Rheum Dis 2003; 62: 728-31.
55. Holzmann H, Sollberg S, Altmeyer P. Klassifikation der progressiven systemischen Sklerose. Hautarzt 1987; 38: 253-7.
56. Hong KH, Yoo SA, Kang SS et al. Hypoxia induces expression of connective tissue growth factor in scleroderma skin fibroblasts. Clin Exp Immunol 2006; 146: 362-70.
57. Horstmeyer A, Licht C, Scherr G, Eckes B, Krieg T. Signalling and regulation of collagen I synthesis by ET-1 and TGF-beta1. FEBS J 2005; 272: 6297-309.
58. Hubmacher D, Tiedemann K, Reinhardt DP. Fibrillins. From biogenesis of microfibrils to signaling functions. Curr Top Dev Biol 2006; 75: 93-123.
59. Hunzelmann N, Genth E, Krieg T, Lehmacher W, Melchers I, Meurer M, Moinzadeh P, Müller-Ladner U, Pfeiffer C, Riemekasten G, Schulze-Lohoff E, Sunderkoetter C, Weber M, Worm M, Klaus P, Rubbert A, Steinbrink K, Grundt B, Hein R, Scharffetter-Kochanek K, Hinrichs R, Walker K, Szeimies RM, Karrer S, Müller A, Seitz C, Schmidt E, Lehmann P, Foeldvári I, Reichenberger F, Gross WL, Kuhn A, Haust M, Reich K, Böhm M, Saar P, Fierlbeck G, Kötter I, Lorenz HM, Blank N, Gräfenstein K, Juche A, Aberer E, Bali G, Fiehn C, Stadler R, Bartels V. Registry of the German Network for Systemic Scleroderma. The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology 2008; 47: 1185-92.
60. Hunzelmann N, Genth E, Krieg T, Meurer M, Melchers I, Moinzadeh P, Pfeiffer C, Riemekasten G, Schulze-Lohoff E, Sunderkoetter C, Müller-Ladner U. Organspezifische Diagnostik von Patienten mit systemischer Sklerose. Empfehlungen des Deutschen Netzwerkes für Systemische Sklerose (DNSS). Z Rheumatol 2008; 67: 334-40.
61. Hunzelmann N, Brinckmann J. What are the new milestones in the pathogenesis of systemic sclerosis? Ann Rheum Dis 2010; 69 (Suppl1): i52-6.
62. Jacobsen S, Halberg P, Ullman S. Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma). Br J Rheumatol1998; 37: 750-5.
63. Janevski B. Arteries of the hand in patients with scleroderma. Diagn Imag Clin Med 1986; 55: 262-5.
64. Janosik DL, Osborn TG, Moore TL, Shah DG, Kenney RG, Zuckner J. Heart disease in systemic sclerosis.Semin Arthritis Rheum 1989; 19: 191-200.
65. Johnson KL, Nelson JL, Furst DE, McSweeney PA, Roberts DJ, Zhen DK, Bianchi DW. Fetal cell microchimerism in tissue from multiple sites in women with systemic sclerosis. Arthritis Rheum 2001; 44: 1848-54.
66. Kähäri VM, Sandberg M, Kalimo H, Vuorio T, Vuorio E. Identification of fibroblasts responsible for increased collagen production in localized scleroderma by in situ hybridization. J Invest Dermatol 1988; 90: 664-70.
67. Kawakami T, Ihn H, Xu W, et al. Incresed expression of TGF-beta receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-beta signaling to scleroderma phenotype. J Invest Dermatol 1998; 110: 47-51. (Pubitemid 28086062)
68. Khurma V, Meyer C, Park GS, McMahon M, Lin J, Singh RR, Khanna D. A pilot study of subclinical coronary atherosclerosis in systemic sclerosis: coronary artery calcification in cases and controls. Arthritis Rheum 2008; 59: 591-7. (Pubitemid 351563544)
69. Klein-Weigel P, Gutsche-Petrak B, Humpel C, Riemekasten G, Ivanov S, Heidrich H, Circulating nerve growth factor in primary and secondary Raynaud's syndrome - Results of a pilot study.VASA 2009; 1: 39-45.
70. Kobayashi H, Yokoe I, Hirano M, Nakamura T, Nakajima Y, Fontaine KR, Giles JT, Kobayashi Y. Cardiac magnetic resonance imaging with pharmacological stress perfusion and delayed enhancement in asymptomatic patients with systemic sclerosis. J Rheumatol 2009; 36: 106-12.
71. Kowal-Bielecka O, Avouac J, Pittrow D, Huscher D, Behrens F, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Nash P, Opitz CF, Rubin LJ, Seibold JR, Strand V, Furst DE, Distler O. EPOSS Group. Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension: a systematic literature analysis by the EPOSS group. J Rheumatol 2010; 37: 105-15.
72. Krieg T, Hunzelmann N. Aktuelle pathophysiologische Aspekte der systemischen Sklerose. Z Rheumatol 2006; 65: 275-8. (Pubitemid 44124536)
73. Kurasawa K, Hirose K, Sano H, Endo H, Shinkai H, Nawata Y, Takabayashi K, Iwamoto I. Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum 2000; 43: 2455-63.
74. Kuwana M, Okazaki Y, Yasuoka H, Kawakami Y, Ikeda Y. Defective vasculogenesis in systemic sclerosis. Lancet 2004; 364: 603-10.
75. Launay D, Remy-Jardin M, Michon-Pasturel U, Mastora I, Hachulla E, Lambert M, Delannoy V, Queyrel V, Duhamel A, Matran R, De Groote P, Hatron PY. High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. J Rheumatol 2006; 33: 1789-1801. (Pubitemid 44373213)
76. Launay D, Mouthon L, Hachulla E, Pagnoux C, de Groote P, Remy-Jardin M, Matran R, Lambert M, Queyrel V, Morell-Dubois S, Guillevin L, Hatron PY. Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease. J Rheumatol 2007; 34: 1005-11.
77. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, Heyse SP, Hirsch R, Hochberg MC, Hunder GG, Liang MH, Pillemer SR, Steen VD, Wolfe F. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998; 41: 778-99.
78. Leask A, Abraham DJ. TGFbeta signaling and the fibrotic response. FASEB J 2004; 18: 816-27.
79. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wollheim F. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-5.
80. LeRoy EC. Systemic sclerosis. A vascular perspective. Rheum Dis Clin North Am 1996; 22: 675-94.
81. LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28: 1573-6.
82. Livi R, Teghini L, Pignone A, Generini S, Matucci-Cerinic M, Cagnoni M. Renal functional reserve is impaired in patients with systemic sclerosis without clinical signs of kidney involvement. Ann Rheum Dis 2002; 61: 682-6.
83. Lonzetti LS, Joyal F, Raynauld JP, Roussin A, Goulet JR, Rich E, Choquette D, Raymond Y, Senécal JL. Updating the American College of Rheumatology preliminary classification criteria for systemic sclerosis: addition of severe nailfold capillaroscopy abnormalities markedly increases the sensitivity for limited scleroderma. Arthritis Rheum 2001; 44: 735-6.
84. Marie I, Ducrotté P, Denis P, Menard JF, Levesque H. Small intestinal bacterial overgrowth in systemic sclerosis. Rheumatology 2009; 48: 1314-9.
85. Masi AT, Rodnan GP, Medsger T et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
86. Mayes MD. Scleroderma epidemiology. Rheum Dis Clin North Am 2003; 29: 239-54.
87. McHugh NJ, Distler O, Giacomelli R, Riemekasten G. Non organ based laboratory markers in systemic sclerosis.Clin Exp Rheumatol 2003; 21 (Suppl 29): S32-8.
88. Medsger TA Jr, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W. Assessment of disease severity and prognosis. Clin Exp Rheumatol 2003; 21 (3 Suppl 29): S42-6.
89. Meli M et al. Predictive value of nailfold capillaroscopy in patients with Raynaud's phenomenon. Clin Rheumatol 2006; 25: 153-8.
90. Osial TA Jr, Whiteside TL, Buckingham RB, Singh G, Barnes EL, Pierce JM, Rodnan GP. Clinical and serologic study of Sjögren' s syndrome in patients with progressive systemic sclerosis. Arthritis Rheum 1983; 26: 500-8.
91. Pavlov-Dolijanović S, Damjanov N, Ostojić P, Susić G, Stojanović R, Gacić D, Grdinić A. The prognostic value of nailfold capillary changes for the development of connective tissue disease in children and adolescents with primary raynaud phenomenon: A follow-up study of 250 patients. Pediatr Dermatol 2006; 23: 437-42. (Pubitemid 44434848)
92. Poormoghim H, Lucas M, Fertig N, Medsger TA Jr. Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in fortyeight patients. Arthritis Rheum 2000; 43: 444-51. (Pubitemid 30395756)
93. Prescott RJ, Freemont AJ, Jones CJ, Hoyland J, Fielding P. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 1992; 166: 255-63.
94. Reveille JD, Solomon DH. American College of Rheumatology ad hoc Committee on Immunologic Testing Guidelines: Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum 2003; 49: 399-412.
95. Richter JG, Sander O, Schneider M, Klein-Weigel P. Diagnostic algorithm for Raynaud's phenomenon and vascular skin lesions in Systemic Lupus Erythematosus (SLE). Lupus 2010 (accepted for publication).
96. Rigamonti C, Shand LM, Feudjo M et al. Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis. Gut 2006; 55: 388-94. (Pubitemid 43268280)
97. Rosato E, Roumpedaki E, Pisarri S, Salsano F. Digital ischemic necrosis in a patient with systemic sclerosis: the role of laser Doppler perfusion imaging. VASA 2009; 4: 390-3.
98. Rosenthal AK, McLaughlin JK, Gridley G, Nyrén O. Incidence of cancer among patients with systemic sclerosis. Cancer 1995; 76: 910-4.
99. Rudnicka L, Majewski S, Blaszczyk M, Skiendzielewska A, Makiela B, Skopinska M, Jablonska S. Adhesion of peripheral blood mononuclear cells to vascular endothelium in patients with systemic sclerosis (scleroderma). Arthritis Rheum 1992; 35: 771-5.
100. Russo K, Hoch S, Dima C, Varga J, Teodorescu M.Circulating anticentromere CENP-A and CENP-B antibodies in patients with diffuse and limited systemic sclerosis, systemic lupus erythematosus, and rheumatoid arthritis. J Rheumatol 2000; 27: 142-8. (Pubitemid 30058641)
101. Saito Y, Ishikawa H. Ultrastructure of the microvasculature in skin affected by systemic scleroderma. J Dermatol 1976; 3: 127-33.
102. Sander O, Iking-Konert C, Ostendorf B. Taschenatlas Kapillarmikroskopie. Rheumazentrum Rhein-Ruhr, Düsseldorf 2007.
103. Sander O, Sunderkötter C, Kötter I, Wagner I, Becker M, Herrgott I, Schwarting A, Ostendorf B, Iking-Konert C, Genth E. Kapillarmikroskopie: Durchführung und Nomenklatur. Z Rheumatol. 2010; 69: 253-62.
104. Sandusky SB, McGuire L, Smith MT, Wigley FM, Haythornthwaite JA. Fatigue: an overlooked determinant of physical function in scleroderma. Rheumatology 2009; 48: 165-9.
105. Sato S, Fujimoto M, Hasegawa M, Takehara K. Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naïve B cells and diminished but activated B cells. Arthritis Rheum 2004; 50: 1918-27. (Pubitemid 38725103)
106. Scharffetter K, Lankat-Buttgereit B, Krieg T. Localization of collagen mRNA in normal and scleroderma skin by in-situ hybridization. Eur J Clin Invest 1988; 18: 9-17.
107. Schlattmann P, Höhne J, Plümper M, Heidrich H. The association of Raynaud's phenomenon/syndrome with scleroderma and Sjögren's syndrome-a meta-analysis. VASA 2008; S73: 26-32.
108. Schmidt JA, Caspary I, von Bierbrauer A, Ehrly AM, Jünger M, Jung F, Lawall H. Standardisierung der Nagelfalz-Kapillarmikroskopie in der Routinediagnostik. VASA 1997; 26: 5-10.
109. Scussel-Lonzetti L, Joyal F, Raynauld JP, Roussin A, Rich E, Goulet JR, Raymond Y, Senécal JL. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine 2002; 81: 154-167. (Pubitemid 34218570)
110. Sharp GC, Irvin WS, Tan EM et al. Mixed connective tissue disease. Anapparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 1972; 52: 148-59.
111. Sollberg S, Mauch C, Eches B, Krieg T. The fibroblast in systemic sclerosis. Clin Dermatol 1994; 12: 379.
112. Spencer-Green G. Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of a transition to secondary disease. Arch Int Med 1998; 158; 596-600.
113. Steen VD, Medsger, TA Jr. The palpable tendon friction rub. An important physical examination finding in patients with systemic sclerosis. Arthritis Rheum 1997; 40: 1146-51.
114. Steen V, Medsger TA, Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003; 48: 516-22.
115. Steen VD. Scleroderma renal crisis.Rheum Dis Clin North Am 2003; 29: 315-33.
116. Strange C, Bolster MB, Roth MD, Silver RM, Theodore A, Goldin J, Clements P, Chung J, Elashoff RM, Suh R, Smith EA, Furst DE, Tashkin DP; Scleroderma Lung Study Research Group. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med 2008; 177: 91-8.
117. Stupi AM, Steen VD, Owens GR, Barnes EL, Rodnan GP, Medsger TA Jr. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986; 29: 515-24.
118. Sunderkötter C, Riemekasten G. Pathophysiology and clinical consequences of Raynaud's phenomenon related to systemic sclerosis. Rheumatology 2006; 45 (Suppl 3): iii33-5.
119. Sunderkötter C, Herrgott I, Brückner C, Moinzadeh P, Pfeiffer C, Gerss J, Hunzelmann N, Böhm M, Krieg T, Müller-Ladner U, Genth E, Schulze-Lohoff E, Meurer M, Melchers I, Riemekasten G; DNSS Centers. Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors.Br J Dermatol 2009; 160: 835-43.
120. Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC); European Respiratory Society (ERS); International Society of Heart and Lung Transplantation (ISHLT), Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34: 1219-63.
121. Teixeira L, Mahr A, Berezné A, Noël LH, Guillevin L, Mouthon L. Scleroderma renal crisis, still a life-threatening complication. Ann N Y Acad Sci 2007; 1108: 249-58.
122. Theander E, Jacobsson LT. Relationship of Sjögren's syndrome to other connective tissue and autoimmune disorders.Rheum Dis Clin North Am 2008; 34: 935-47.
123. Valentini G, Della Rossa A, Bombardieri S, Bencivelli W, Silman AJ, D'Angelo S, Cerinic MM, Belch JF, Black CM, Bruhlmann P, Czirják L, De Luca A, Drosos AA, Ferri C, Gabrielli A, Giacomelli R, Hayem G, Inanc M, McHugh NJ, Nielsen H, Rosada M, Scorza R, Stork J, Sysa A, van den Hoogen FH, Vlachoyiannopoulos PJ. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 2001; 60: 592-8.
124. Winterbauer RH. Multiple Teleangiectasia, Raynaud's phenomenon, Sclerodactyly, and subcutaneous calcinosis: a syndrome mimicking hereditary hemorrhagis teleangiectasia. Bull Johns Hopkins Hosp 1964; 114: 361-83.
125. Zuber JP, Spertini F. Immunological basis of systemic sclerosis. Rheumatology 2006; 45 (Suppl 3): iii23-5.